Market Overview

Acadia Pharma Announces $86M Equity Financing

Related ACAD
4 Biotech Stocks Worth A Look Ahead Of FDA Approvals
Benzinga's Top Initiations

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced a private placement equity financing pursuant to which ACADIA will receive gross proceeds of $86.4 million from the sale of its securities. Shares of ACADIA's common stock will be sold at $4.43 per share, the closing market price on December 11, 2012. The private placement is expected to close on December 17, 2012 and is subject to the satisfaction of customary closing conditions.

Posted-In: News Financing

 

Most Popular

Related Articles (ACAD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free